White & Case has advised an investor consortium that includes Singaporean sovereign wealth fund Temasek on its purchase of a majority stake in U.S. pharmaceuticals company Alvogen from Pamplona Capital Management.
The size of the controlling stake was not disclosed, although Reuters reported the deal values Alvogen at about $2 billion. In an interview with the newswire, CEO Robert Wessman said the generic drugmaker, which currently sells 350 products in 35 countries, plans to “build up one of the leading positions in Asia Pacific.” The company has been making acquisitions in the region to boost its footprint there, including the purchase of South Korea’s Dream Pharma for $187 million last year.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
